Management Team
|
Timo Veromaa
Born: 1960
Education: M.D., Ph.D., special competence in pharmaceutical medicine
Position at Biotie: President and CEO
Appointed as member of the Management Team: December 1998
Employment history: Biotie Therapies Corp., Vice President of R&D 1998–2005. President and CEO from 2005. Schering Oy, Medical Director 1996–1998. Collagen Corporation (California, USA), research and program manager 1994–1996. Stanford University (California, USA), Postdoc Fellow 1990–1993. University of Turku, scientist 1985–1990.
Key positions of trust: Finnish Bioindustries, Chairman of the Board. Chairman of the Steering Committee for HealthBIO, a national cluster program focusing on health applications of biotechnology and on business areas related to health. Chemical Industry Federation of Finland, Member of the Board of Directors.
Number of shares held in Biotie |
|
Ian Massey
Born: 1950
Education: D.Phil degree in Chemistry
Position at Biotie: Chief Operating Officer and President of US operations
Appointed as member of the Management Team: February 2011
Employment history: Founder and President and CEO of Synosia Therapeutics; Roche from 1995 to 2006, Senior Vice President and Head of Research and Preclinical Development, Senior Vice President and Head of the Neurobiology Business Unit and Central Research and Development for Roche Bioscience; Syntex Research, a series of senior roles in Research and Development
Key positions of trust: Director of QLT Inc
Number of shares held in Biotie February 2011: 1,798,868
Maximum number of shares to be subscribed based on option rights February 2011: 2,646,236
Option program: Swiss option plan
|
|
Chris Piggott
Born: 1952
Education: M.A.
Position at Biotie: Chief Business Officer
Appointed as member of the Management Team: June 2009
Employment history: sanofi -aventis, VP Business Intelligence 2005–2007. Aventis, Senior Director, Business Development, 1998–2005. Hoechst Marion Roussel (UK), Head of Business Development & Strategic Marketing 1995–1998. Marion Merrell Dow (UK), Director of Marketing, 1991–1995. Merrell Dow (Switzerland), commercial positions including General Manager, MidEast/Africa, 1981–1991. Rhone Poulenc (UK), sales and marketing positions, 1974–1981. University of Cambridge, UK,M.A. in Pharmacology 1973
Key positions of trust: None
Number of shares held in Biotie 31.12.2010: –
Number of option rights 31.12.2010:
Option program: 2006: –; 2009: 500,000 |
|
Zack McNealy
Born: 1974
Education: B.Sci. (Accounting & Finance)
Position at Biotie: interim CFO
Appointed as member of the Management Team: September 2011
Employment history:
Biotie Therapies, VP Finance 2011. Synosia Therapeutics, VP Finance/Controller 2007-2010. Johnson & Johnson, Plant Controller/Finance Manager/Financial Analyst 1997-2006
Number of shares held in Biotie September 2011: –
Maximum number of shares to be subscribed based on option rights September 2011: 889,226
Option program: Swiss option plan |
|
Stephen Bandak
Born: 1950 Education: M.D.
Position at Biotie: Chief Medical Officer
Appointed as member of the Management Team: February 2011
Employment history: Synosia Therapeutics AG, CMO from 2007 to 2011; Novavax, Vice President of Medical and Regulatory from 2004 to 2006; Eli Lilly and Company, a variety of leadership roles including Executive Director of the US Medical Organization; Member the Royal College of Physicians 1977
Key positions of trust: Director of Hapten Sciences Inc.
Number of shares held in Biotie February .2011: –
Maximum number of shares to be subscribed based on option rights February 2011: 1,706,021
Option program: Swiss option plan
---
Updated January 10, 2012 |
|